Human cytochrome-P450 enzymes metabolize N-(2-methoxyphenyl)hydroxylamine, a metabolite of the carcinogens o-anisidine and o-nitroanisole, thereby dictating its genotoxicity

Mutation Research - Genetic Toxicology and Environmental Mutagenesis

Volumn 726, Issue 2, 2011, Pages 160-168

  Naiman, Karel ^a   Martínková, Markéta ^a   Schmeiser, Heinz H ^b   Frei, Eva ^b   Stiborová, Marie ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

Cytochromes P450; Metabolism; N (2 Methoxyphenyl)hydroxylamine; O Anisidine; O Nitroanisole

Indexed keywords

2 ANISIDINE; 2 NITROANISOLE; ANILINE DERIVATIVE; BENZENE DERIVATIVE; CARCINOGEN; CYTOCHROME P450; CYTOCHROME P450 2A6; CYTOCHROME P450 2C; CYTOCHROME P450 2D6; CYTOCHROME P450 2E1; CYTOCHROME P450 3A4; DEOXYGUANOSINE; DNA; LIVER ENZYME; MICROSOME ENZYME; N (2 METHOXYPHENYL)HYDROXYLAMINE; PHOSPHORUS 32; RECOMBINANT ENZYME; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ARTICLE; BLADDER CANCER; CHEMICAL CARCINOGENESIS; DECOMPOSITION; DNA ADDUCT; DNA BINDING; ENZYME ACTIVITY; GENOTOXICITY; HUMAN; HUMAN TISSUE; ISOTOPE LABELING; LIVER MICROSOME; MALE; METABOLITE; NONHUMAN; POLLUTANT; PRIORITY JOURNAL; RAT;

ANILINE COMPOUNDS; ANIMALS; ANISOLES; CARCINOGENS; CYTOCHROME P-450 ENZYME SYSTEM; DNA ADDUCTS; ENVIRONMENTAL POLLUTANTS; HUMANS; HYDROXYLAMINES; MALE; MICROSOMES, LIVER; RATS; RATS, WISTAR;

EID: 81055140330     PISSN: 13835718     EISSN: 18793592     Source Type: Journal    
DOI: 10.1016/j.mrgentox.2011.09.010     Document Type: Article

References (58)

1. National Cancer Institute, Bioassay of o-anisidine hydrochloride for possible carcinogenicity, NTP Technical Report No. 89, National Cancer Institute, Bethesda, MD, 1978.
2. IARC Ortho- and para-anisidine and their hydrochlorides. IARC Monographs on the Evaluation of the Carcinogenic Risk of Chemicals in Humans, vol. 27 1982, pp. 63-80.
3. IARC Ortho-anisidine. Some chemicals that cause tumors of the kidney or urinary bladder in rodents and some other substances. IARC Monographs on the Evaluation of Carcinogenic Risk of Chemicals to Humans, vol. 73 1999, pp. 49-58.
4. Garner R.C., Martin C.N., Clayson D.B. Carcinogenic aromatic amines and related compounds. Chemical Carcinogens, vol. 1, 3rd ed., ACS Monograph No. 182 1984, 175-302. American Chemical Society, Washington, DC. C.E. Searle (Ed.).
5. Stabbert R., Schäfer K.-H., Biefel C., Rustemeier K. Analysis of aromatic amines in cigarette smoke. Rapid Commun. Mass Spectrom. 2003, 17:2125-2132.
6. Weiss T., Angerer J. Simultaneous determination of various aromatic amines and metabolites of aromatic nitro compounds in urine for low level exposure using gas chromatography-mass spectrometry. J. Chromatogr. B 2002, 778:179-192.
7. Branner B., Kutzer C., Zwickenpflug W., Scherer G., Heller W.-D., Richter E. Haemoglobin adducts from aromatic amines and tobacco-specific nitrosamines in pregnant smoking and non-smoking women. Biomarkers 1998, 3:35-47.
8. Richter E., Rösler S., Scherer G., Gostomzyk J.G., Grübl A., Krämer U., Behrendt H. Haemoglobin adducts from aromatic amines in children in relation to area of residence and exposure to environmental tobacco smoke. Int. Arch. Occup. Environ. Health 2001, 74:421-428.
9. Hauthal H.G. Rosenmontag und die Folgen: die Störfälle der Hoechst AG. Nach. Chem. Tech. Lab. 1993, 41:440.
10. Traupe H., Menge G., Kandt J., Karmaus W. Higher frequency of atopic dermatitis and decrease in viral warts among children exposed to chemicals liberated in a chemical accident in Frankfurt, Germany. Dermatology 1997, 195:112-118.
11. National Cancer Institute, Toxicology and Carcinogenesis. Studies of 2-nitroanisole. NTP Technical Report No. 416, National Institute of Health, US Department of Health and Human Services, Bethesda, MD, 1993.
12. IARC. Printing processes and printing inks, carbon black and some nitro compounds, in: IARC Monographs on the Evaluation of Carcinogenic Risk of Chemicals to Humans, Vol. 65, 1996, p. 578.
13. 32P-postlabelling analysis of DNA adducts formation. Gen. Physiol. Biophys. 2001, 20:267-279.
14. Stiborová M., Mikšanová M., Havlíček V., Schmeiser H.H., Frei E. Mechanism of peroxidase-mediated oxidation of carcinogenic o-anisidine and its binding to DNA. Mutat. Res. 2002, 500:49-66.
15. Stiborová M., Mikšanová M., Šulc M., Rýdlová H., Schmeiser H.H., Frei E. Identification of a genotoxic mechanism for the carcinogenicity of the environmental pollutant and suspected human carcinogen o-anisidine. Int. J. Cancer 2005, 116:667-678.
16. Rýdlová H., Mikšanová M., Ryšlavá H., Stiborová M. Carcinogenic pollutants o-nitroanisole and o-anisidine are substrates and inducers of cytochromes P450. Biomed. Pap. Med. Fac. Univ. Palacky Olomouc Czech Repub. 2005, 49:441-447.
17. Naiman K., Dračínská H., Martínková M., Šulc M., Dračínský M., Kejíková L., Hodek P., Hudeček J., Liberda J., Schmeiser H.H., Frei E., Stiborová M. Redox cycling in the metabolism of the environmental pollutant and suspected human carcinogen o-anisidine by rat and rabbit hepatic microsomes. Chem. Res. Toxicol. 2008, 21:1610-1621.
18. Stiborová M., Mikšanová M., Smrček S., Bieler C.A., Breuer A., Klokow K.A., Schmeiser H.H., Frei E. Identification of a genotoxic mechanism for 2-nitroanisole carcinogenicity and of its carcinogenic potential for humans. Carcinogenesis 2004, 25:833-840.
19. Stiborová M., Schmeiser H.H., Frei E. To the mechanism of 2-nitroanisole carcinogenicity: in vitro metabolism of 2-nitroanisole mediated by peroxidases and xanthine oxidase. Collect. Czech Chem. Commun. 1998, 63:857-869.
20. Mikšanová M., Novák P., Frei E., Stiborová M. Metabolism of carcinogenic 2-nitroanisole by rat, rabbit, porcine and human hepatic cytosol. Collect. Czech Chem, Commun. 2004, 69:589-602.
21. Naiman K., Hodek P., Liberda J., Schmeiser H.H., Frei E., Stiborová M. Rat liver microsomal metabolism of o-aminophenol and N-(2-methoxyphenyl)hydroxylamine, two metabolites of the environmental pollutant and carcinogen o-anisidine in humans. Collect. Czech Chem. Commun. 2010, 75:1229-1247.
22. Naiman K., Frei E., Stiborová M. Identification of rat cytochromes P450 metabolizing N-(2-methoxyphenyl)hydroxylamine, a human metabolite of the environmental pollutants and carcinogens o-anisidine and o-nitroanisole. Neuro Endocrinol. Lett. 2010, 31(Suppl. 2):36-45.
23. Balaban A.T., Garfield R.E., Lesko M.J., Seitz W.A. Synthesis and spectral data of some new N-nitroso-N-phenylhydroxylamine (cupferron) derivatives. Org. Prep. Proced. Int. 1998, 30:439-446.
24. Seidenfaden W. Methoden der Organischen Chemie (Houben-Weyl) 1971, Band X/1, Georg Thieme Verlag, Stuttgart, p. 1058.
25. Stiborová M., Breuer A., Aimová D., Stiborová-Rupertová M., Wiessler M., Frei E. DNA adduct formation by the anticancer drug ellipticine in rats determined by 32P-postlabeling. Int. J. Cancer 2003, 107:885-890.
26. Svobodová M., Martínková M., Dračínská H., Frei E., Stiborová M. Rat cytochromes P450 oxidize 2-nitrophenol, a human metabolite of carcinogenic 2-nitroanisole. Neuro Endocrinol. Lett. 2009, 30(Suppl. 1):46-51.
27. Wiechelman K.J., Braun R.D., Fitzpatrick J.D. Investigation of the bicinchoninic acid protein assay: identification of the groups responsible for color formation. Anal. Biochem. 1988, 175:231-237.
28. Omura T., Sato R. The carbon monoxide-binding pigment of liver microsomes. I. Evidence for its hemoprotein nature. J. Biol. Chem. 1964, 239:2370-2378.
29. Sottocasa G.L., Kuylenstierna I., Ernster I., Bergstrand A. An electron transport system associated with the outer membrane of liver mitochondria. J. Cell. Biol. 1967, 32:415-438.
30. Strobel H.W., Dignam J.D. Purification and properties of NADPH-cytochrome P-450 reductase. Methods Enzymol. 1978, 52:89-96.
31. Rendic S., DiCarlo F.J. Human cytochrome P450 enzymes: a status report summarizing their reactions, substrates, inducers, and inhibitors. Drug Metab. Rev. 1997, 29:413-480.
32. Stiborová M., Martínek V., Rýdlová H., Hodek P., Frei E. Sudan I is a potential carcinogen for humans: evidence for its metabolic activation and detoxication by human recombinant cytochrome P450 1A1 and liver microsomes. Cancer Res. 2002, 62:5678-5684.
33. Stiborová M., Martínek V., Rýdlová H., Koblas T., Hodek P. Expression of cytochrome P450 1A1 and its contribution to oxidation of a potential human carcinogen 1-phenylazo-2-naphthol (Sudan I) in human livers. Cancer Lett. 2005, 220:145-154.
34. Slepneva I.A., Sergeeva S.V., Khramtsov V.V. Reversible inhibition of NADPH-cytochrome P450 reductase by α-lipoic acid. Biochem. Biophys. Res. Commun. 1995, 214:1246-1253.
35. Okabe N., Fujiwara T., Yamagata Y., Tomita K. Structure of a potent antithyroid drug, 6-propyl-2-thiouracil. Bull. Chem. Soc. Jpn. 1983, 56:1543-1544.
36. 32P-postlabeling analysis of nonradioactive aromatic carcinogen-DNA adducts. Carcinogenesis 1982, 3:1081-1092.
37. 32P-postlabelling test for structurally diverse DNA adducts. Carcinogenesis 1986, 7:1543-1551.
38. 32P-postlabeling of adducts as labeled nucleoside bisphosphates, dinucleotides and nucleoside monophosphates. Carcinogenesis 1990, 8:1349-1357.
39. Sesardic D., Boobis A.R., Murray B.P., Murray S., Segura J., de la Torre R., Davies D.S. Furafylline is a potent and selective inhibitor of cytochrome P450IA2 in man. Br. J. Clin. Pharmacol. 1990, 29:651-663.
40. Stiborová M., Bořek-Dohalská L., Hodek P., Mráz J., Frei E. New selective inhibitors of cytochromes P450 2B and their application to antimutagenesis of tamoxifen. Arch. Biochem. Biophys. 2002, 403:41-49.
41. 5 or heme oxygenase. J. Biol. Chem. 2001, 276:30885-30891.
42. 5 profoundly affects hepatic and extra-hepatic drug metabolism. Mol. Pharmacol. 2010, 78:269-278.
43. Kim D., Kadlubar F.F., Teitel C.H., Guengerich F.P. Formation and reduction of aryl and heterocyclic nitroso compounds and significance in the flux of hydroxylamines. Chem. Res. Toxicol. 2004, 17:529-536.
44. Lewis D.F.V. Human cytochromes P450 associated with the phase 1 metabolism of drugs and other xenobiotics: a compilation of substrates and inhibitors of the CYP1, CYP2 and CYP3 families. Curr. Med. Chem. 2003, 10:1955-1972.
45. Romkes-Sparks M., Mnuskin A., Chern H.D., Persad R., Fleming C., Sibley G.N., Smith P., Wilkinson G.R., Branch R.A. Correlation of polymorphic expression of CYP2D6 mRNA in bladder mucosa and tumor tissue to in vivo debrisoquine hydroxylase activity. Carcinogenesis 1994, 15:1955-1961.
46. Nakajima M., Itoh M., Sakai H., Fukami T., Katoh M., Yamazaki H., Kadlubar F.F., Imaoka S., Funae Y., Yokoi T. CYP2A13 expressed in human bladder metabolically activates 4-aminobiphenyl. Int. J. Cancer 2006, 119:2520-2526.
47. Saarikoski S.T., Wikman H.A., Smith G., Wolff C.H.J., Husgafvel-Pursiainen K. Localization of cytochrome P450 CYP2S1 expression in human tissues by in situ hybridization and immunohistochemistry. J. Histochem. Cytochem. 2005, 53:549-556.
48. Hou D.F., Wang S.L., He Z.M., Yang F., Chen Z.C. Expression of CYP2E1 in human nasopharynx and its metabolic effect in vitro. Mol. Cell. Biochem. 2007, 298:93-100.
49. Joshi M., Tyndale R.F. Induction and recovery time course of rat brain CYP2E1 after nicotine treatment. Drug Metab. Dispos. 2006, 34:647-652.
50. Kirchner G., Bayer U. Genotoxic activity of the aminophenols as evidenced by the induction of sister chromatid exchanges. Hum. Toxicol. 1992, 1:387-392.
51. Brennan R.J., Schiestl R.H. Aniline and its metabolite generate free radicals in yeast. Mutagenesis 1997, 12:215-220.
52. Brennan R.J., Schiestl R.H. The aromatic amine carcinogens o-toluidine and o-anisidine induce free radicals and intrachromosomal recombination in Saccharomyces cerevisiae. Mutat. Res. 1999, 430:37-45.
53. Okhuma Y., Kawanishi S. Oxidative DNA damage induced by a metabolite of carcinogenic o-anisidine: enhancement of DNA damage and alteration in its sequence specificity by superoxide dismutase. Arch. Biochem. Biophys. 2001, 389:49-56.
54. Beland F.A., Fullerton N.F., Heflich R.H. Rapid isolation, hydrolysis and chromatography of formaldehyde-modified DNA. J. Chromatogr. 1984, 308:121-131.
55. Huang H., Hopkins P.B. DNA interstrand cross-linking by formaldehyde: nucleotide sequence preference and covalent structure of the predominant cross-link formed in synthetic oligonucleotides. J. Am. Chem. Soc. 1993, 115:9402-9408.
56. Cheng G., Shi Y., Sturla S., Jalas J., McIntee E.J., Villalta P.W., Wang M., Hecht S.S. Reactions of formaldehyde plus acetaldehyde with deoxyguanosine and DNA: formation of cyclic deoxyguanosine adducts and formaldehyde cross-links. Chem. Res. Toxicol. 2003, 16:145-152.
57. IARC Formaldehyde, 2-Butoxyethanol and 1-tert-butoxypropan-2-ol. IARC Monographs on the Evaluation of Carcinogenic Risk to Humans, vol. 88 2006, 39-325.
58. Dhareshwar S.S., Stella V.J. Your prodrug releases formaldehyde: should you be concerned? No!. J. Pharm. Sci. 2008, 97:4184-4193.